blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3280417

EP3280417 - XANTHINE-SUBSTITUTED ALKYNYL CARBAMATES/REVERSE CARBAMATES AS A2B ANTAGONISTS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  04.06.2021
Database last updated on 03.10.2024
FormerThe patent has been granted
Status updated on  26.06.2020
FormerGrant of patent is intended
Status updated on  17.09.2019
FormerRequest for examination was made
Status updated on  12.01.2018
FormerThe international publication has been made
Status updated on  31.10.2017
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 09.10.2024 [2024/41]
Applicant(s)For all designated states
Lewis and Clark Pharmaceuticals, Inc.
1180 Seminole Trail
Suite 495
Charlottesville, Virginia 22901 / US
[2018/07]
Inventor(s)01 / THOMPSON, Robert
1180 Seminole Trail
Suite 495
Charlottesville, Virginia 22901 / US
02 / BEAUGLEHOLE, Anthony
1180 Seminole Trail
Suite 495
Charlottesville, Virginia 22901 / US
03 / WANG, Guoquan
1180 Seminole Trail
Suite 495
Charlottesville, Virginia 22901 / US
 [2018/07]
Representative(s)Noréns Patentbyrå AB
Box 10198
100 55 Stockholm / SE
[2018/07]
Application number, filing date16777436.308.04.2016
[2018/07]
WO2016US26807
Priority number, dateUS201562144371P08.04.2015         Original published format: US 201562144371 P
[2018/07]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016164838
Date:13.10.2016
Language:EN
[2016/41]
Type: A1 Application with search report 
No.:EP3280417
Date:14.02.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 13.10.2016 takes the place of the publication of the European patent application.
[2018/07]
Type: B1 Patent specification 
No.:EP3280417
Date:29.07.2020
Language:EN
[2020/31]
Search report(s)International search report - published on:US13.10.2016
(Supplementary) European search report - dispatched on:EP03.01.2019
ClassificationIPC:C07D473/06, A61K31/522, A61P3/04, A61P3/10, A61P11/06, A61P29/00, A61P35/00, A61P37/00
[2019/37]
CPC:
C07D473/06 (EP,IL,KR,US); A61K31/522 (KR); A61P11/06 (EP,IL,US);
A61P29/00 (EP,IL,US); A61P3/04 (EP,US); A61P3/10 (EP,US);
A61P35/00 (EP,IL,US); A61P37/00 (EP,IL,US) (-)
Former IPC [2019/04]C07D473/06, A61K31/522, A61P3/04, A61P29/00, A61P35/00, A61P37/00, A61P11/06, A61P3/10
Former IPC [2018/07]A61K31/522, C07D473/04, A61K31/519, A61K31/52, C07D473/00, C07D473/06
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/07]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:XANTHIN-SUBSTITUIERTE ALKYNYLCARBAMATE/REVERSE CARBAMATE ALS A2B-ANTAGONISTEN[2019/37]
English:XANTHINE-SUBSTITUTED ALKYNYL CARBAMATES/REVERSE CARBAMATES AS A2B ANTAGONISTS[2018/07]
French:CARBAMATES D'ALCYNYLE SUBSTITUÉS PAR XANTHINE/CARBAMATES INVERSES UTILISÉS EN TANT QU'ANTAGONISTES D'A2B[2018/07]
Former [2018/07]XANTHIN-SUBSTITUIERTE ALKYNYLCARBAMATE/REVERSE-CARBAMATE ALS A2B-ANTAGONISTEN
Entry into regional phase31.10.2017National basic fee paid 
31.10.2017Search fee paid 
31.10.2017Designation fee(s) paid 
31.10.2017Examination fee paid 
Examination procedure31.10.2017Examination requested  [2018/07]
31.10.2017Date on which the examining division has become responsible
10.06.2018Loss of particular rights, legal effect: Claims
23.07.2018Despatch of communication of loss of particular rights: Claims {1}
23.07.2019Amendment by applicant (claims and/or description)
18.09.2019Communication of intention to grant the patent
06.03.2020Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
08.05.2020Fee for grant paid
08.05.2020Fee for publishing/printing paid
08.05.2020Receipt of the translation of the claim(s)
Opposition(s)30.04.2021No opposition filed within time limit [2021/27]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
08.05.2020Request for further processing filed
08.05.2020Full payment received (date of receipt of payment)
Request granted
02.06.2020Decision despatched
08.05.2020Request for further processing filed
08.05.2020Full payment received (date of receipt of payment)
Request granted
02.06.2020Decision despatched
Fees paidRenewal fee
15.10.2018Renewal fee patent year 03
01.03.2019Renewal fee patent year 04
25.03.2020Renewal fee patent year 05
Penalty fee
Additional fee for renewal fee
30.04.201803   M06   Fee paid on   15.10.2018
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU08.04.2016
AL29.07.2020
AT29.07.2020
CY29.07.2020
EE29.07.2020
FI29.07.2020
HR29.07.2020
LT29.07.2020
LV29.07.2020
MC29.07.2020
MK29.07.2020
MT29.07.2020
RO29.07.2020
RS29.07.2020
SI29.07.2020
SK29.07.2020
SM29.07.2020
BG29.10.2020
NO29.10.2020
GR30.10.2020
IS29.11.2020
LU08.04.2021
[2024/41]
Former [2024/22]HU08.04.2016
AL29.07.2020
AT29.07.2020
CY29.07.2020
EE29.07.2020
FI29.07.2020
HR29.07.2020
LT29.07.2020
LV29.07.2020
MC29.07.2020
MK29.07.2020
RO29.07.2020
RS29.07.2020
SI29.07.2020
SK29.07.2020
SM29.07.2020
BG29.10.2020
NO29.10.2020
GR30.10.2020
IS29.11.2020
LU08.04.2021
Former [2023/30]HU08.04.2016
AL29.07.2020
AT29.07.2020
CY29.07.2020
EE29.07.2020
FI29.07.2020
HR29.07.2020
LT29.07.2020
LV29.07.2020
MC29.07.2020
RO29.07.2020
RS29.07.2020
SI29.07.2020
SK29.07.2020
SM29.07.2020
BG29.10.2020
NO29.10.2020
GR30.10.2020
IS29.11.2020
LU08.04.2021
Former [2023/28]HU08.04.2016
AL29.07.2020
AT29.07.2020
EE29.07.2020
FI29.07.2020
HR29.07.2020
LT29.07.2020
LV29.07.2020
MC29.07.2020
RO29.07.2020
RS29.07.2020
SI29.07.2020
SK29.07.2020
SM29.07.2020
BG29.10.2020
NO29.10.2020
GR30.10.2020
IS29.11.2020
LU08.04.2021
Former [2022/23]AL29.07.2020
AT29.07.2020
EE29.07.2020
FI29.07.2020
HR29.07.2020
LT29.07.2020
LV29.07.2020
MC29.07.2020
RO29.07.2020
RS29.07.2020
SI29.07.2020
SK29.07.2020
SM29.07.2020
BG29.10.2020
NO29.10.2020
GR30.10.2020
IS29.11.2020
LU08.04.2021
Former [2022/10]AL29.07.2020
AT29.07.2020
EE29.07.2020
FI29.07.2020
HR29.07.2020
LT29.07.2020
LV29.07.2020
MC29.07.2020
RO29.07.2020
RS29.07.2020
SI29.07.2020
SK29.07.2020
SM29.07.2020
BG29.10.2020
NO29.10.2020
GR30.10.2020
LU08.04.2021
Former [2022/04]AL29.07.2020
AT29.07.2020
EE29.07.2020
FI29.07.2020
HR29.07.2020
LT29.07.2020
LV29.07.2020
MC29.07.2020
RO29.07.2020
RS29.07.2020
SI29.07.2020
SK29.07.2020
SM29.07.2020
BG29.10.2020
NO29.10.2020
GR30.10.2020
IS29.11.2020
LU08.04.2021
Former [2021/50]AL29.07.2020
AT29.07.2020
EE29.07.2020
FI29.07.2020
HR29.07.2020
LT29.07.2020
LV29.07.2020
MC29.07.2020
RO29.07.2020
RS29.07.2020
SI29.07.2020
SK29.07.2020
SM29.07.2020
BG29.10.2020
NO29.10.2020
GR30.10.2020
IS29.11.2020
Former [2021/36]AL29.07.2020
AT29.07.2020
EE29.07.2020
FI29.07.2020
HR29.07.2020
LT29.07.2020
LV29.07.2020
RO29.07.2020
RS29.07.2020
SI29.07.2020
SK29.07.2020
SM29.07.2020
BG29.10.2020
NO29.10.2020
GR30.10.2020
IS29.11.2020
Former [2021/28]AL29.07.2020
AT29.07.2020
EE29.07.2020
FI29.07.2020
HR29.07.2020
LT29.07.2020
LV29.07.2020
RO29.07.2020
RS29.07.2020
SK29.07.2020
SM29.07.2020
BG29.10.2020
NO29.10.2020
GR30.10.2020
IS29.11.2020
Former [2021/25]AL29.07.2020
AT29.07.2020
EE29.07.2020
FI29.07.2020
HR29.07.2020
LT29.07.2020
LV29.07.2020
RO29.07.2020
RS29.07.2020
SM29.07.2020
BG29.10.2020
NO29.10.2020
GR30.10.2020
IS29.11.2020
Former [2021/22]AT29.07.2020
EE29.07.2020
FI29.07.2020
HR29.07.2020
LT29.07.2020
LV29.07.2020
RO29.07.2020
RS29.07.2020
SM29.07.2020
BG29.10.2020
NO29.10.2020
GR30.10.2020
IS29.11.2020
Former [2021/10]AT29.07.2020
FI29.07.2020
HR29.07.2020
LT29.07.2020
LV29.07.2020
RS29.07.2020
BG29.10.2020
NO29.10.2020
GR30.10.2020
IS29.11.2020
Former [2021/08]FI29.07.2020
LT29.07.2020
BG29.10.2020
NO29.10.2020
Former [2021/07]FI29.07.2020
LT29.07.2020
NO29.10.2020
Documents cited:Search[A]WO2006091896  (ADENOSINE THERAPEUTICS LLC [US], et al) [A] 1-15 * abstract * * page 27; example - *;
 [A]US2009163491  (THOMPSON ROBERT D [US], et al) [A] 1-15 * abstract *;
 [A]WO2011005871  (PGXHEALTH LLC [US], et al) [A] 1-15 * abstract * * pages 42, 46; compounds 3C, 4Y, 4Z *;
 [A]  - MÜLLER, C.E. ET AL., "Recent developments in adenosine receptor ligands and their potential as novel drugs", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - BIOMEMBRANES, vol. 1808, no. 5, doi:10.1016/J.BBAMEM.2010.12.017, ISSN 0005-2736, (2010), pages 1290 - 1308, (20101223), XP028157805 [A] 1-15 * abstract * * page 1297; figure 7; compound 68 *

DOI:   http://dx.doi.org/10.1016/j.bbamem.2010.12.017
International search[A]US8044061  (MUELLER CHRISTA E [DE], et al) [A] 1-21 * entire document *;
 [A]US2014275071  (CHENARD BERTRAND L [US], et al) [A] 1-21 * entire document *;
 [A]  - "CID 113701061", PUBCHEM, (20110320), Database accession no. 113701061, URL: ncbi, XP055319540 [A] 1-21 * . entire document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.